Identifying Protein Biomarkers for Congenital Heart Defects
Author Information
Author(s): Nath Anjali K., Krauthammer Michael, Li Puyao, Davidov Eugene, Butler Lucas C., Copel Joshua, Katajamaa Mikko, Oresic Matej, Buhimschi Irina, Buhimschi Catalin, Snyder Michael, Madri Joseph A.
Primary Institution: Yale University
Hypothesis
Proteins involved in cardiac development and congenital heart defects can be isolated and characterized from vascular tissue.
Conclusion
The study identifies WNT16, ST14, and Pcsk1 as potential biomarkers for congenital heart defects, suggesting their role in the etiology of these conditions.
Supporting Evidence
- WNT16, ST14, and Pcsk1 levels were significantly higher in the amniotic fluid of women carrying fetuses with congenital heart defects.
- Statistical analysis showed that these proteins could correctly classify cases with congenital heart defects in up to 89% of instances.
- Mass spectrometry identified 143 peptide peaks dysregulated by hyperglycemia, which were linked to cardiac development.
Takeaway
Researchers found certain proteins that can help predict heart problems in babies before they are born, which could lead to better treatments.
Methodology
Murine embryos were exposed to high glucose, and mass spectrometry was used to identify differentially expressed proteins, which were validated in human amniotic fluid samples.
Potential Biases
Potential biases may arise from the selection of samples and the reliance on specific protein detection methods.
Limitations
The study's findings need further validation in larger cohorts to confirm the specificity and sensitivity of the identified biomarkers.
Participant Demographics
Amniotic fluid samples were obtained from 17 women carrying fetuses with congenital heart defects and 16 women with normal fetuses.
Statistical Information
P-Value
p<0.01 for CHST3
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website